.

Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Daiichi Sankyo
Chubb
Merck
Mallinckrodt
Argus Health
Moodys
Harvard Business School
Accenture
Boehringer Ingelheim

Generated: December 16, 2017

DrugPatentWatch Database Preview

Details for Patent: RE45128

« Back to Dashboard

Which drugs does patent RE45128 protect, and when does it expire?


Patent RE45128 protects SYNRIBO and is included in one NDA. There has been one Paragraph IV challenge on Synribo.

This patent has twenty-six patent family members in seventeen countries.

Summary for Patent: RE45128

Title:Cephalotaxane derivatives and their processes of preparation and purification
Abstract: The present invention concerns a new general process for asymmetric hemisynthesis of harringtonines and their analogs, that are alkaloids used in chemotherapy. This process comprises direct esterification of a natural cephalotaxine with an acylating compound constituted of a side chain precursor which backbone and functionalization are entirely preformed. The invention also concerns a natural, synthetic or semi-synthetic harringtonines including their tautomeric forms and their salts of the following formula: ##STR00001## wherein n=2 (i.e. harringtonine) or n=3 (i.e. homoharringtonine), in which the total content of impurities, possibly including enantiomeric forms, is lower than 1%, and/or the content of the major impurity is lower than 0.9%, and/or the chromatographic assay exhibits a harringtonines content higher than 97.5%.
Inventor(s): Robin; Jean-Pierre (Geneva, CH), Blanchard; Julie (Puyricard, FR), Marie; Jean-Pierre (Sevres, FR), Radosevic; Nina (Geneva, CH)
Assignee: IVAX International GmbH (Rapperswil, CH)
Application Number:13/661,677
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Teva Pharms IntlSYNRIBOomacetaxine mepesuccinatePOWDER;SUBCUTANEOUS203585-001Oct 26, 2012RXYesYes► Subscribe► SubscribeYYTREATMENT OF LEUKEMIA► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: RE45128

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France98 03492Mar 20, 1998

Non-Orange Book Patents for Patent: RE45128

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,613,900 Cephalotaxane derivatives and process for their preparation► Subscribe
7,842,687Cephalotaxane derivatives and their processes of preparation and purification► Subscribe
7,169,774Cephalotaxane derivatives and their processes of preparation and purification► Subscribe
6,831,180 Cephalotaxane derivatives and process for their preparation► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: RE45128

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria289312► Subscribe
Australia2002304338► Subscribe
Australia3270699► Subscribe
Canada2324895► Subscribe
Canada2441428► Subscribe
China1220692► Subscribe
China1300289► Subscribe
Germany69923768► Subscribe
Denmark1064285► Subscribe
European Patent Office1064285► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
McKinsey
Harvard Business School
Johnson and Johnson
Express Scripts
McKesson
Cantor Fitzgerald
Fish and Richardson
Healthtrust
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot